The FDA plans to reduce the number of required pivotal trials in Phase 3 clinical studies from two to one, aiming to streamline drug development. While this may benefit smaller biotech companies, the impact will vary by disease, as some conditions may still necessitate more trials to ensure safety and efficacy.

The FDA plans to allow drug approvals based on a single clinical trial instead of the traditional two. Commissioner Marty Makary stated that this change aims to streamline the approval process while maintaining safety and efficacy standards. Some exceptions will still apply, where two trials may be required.

The FDA is exploring the use of AI, specifically through discussions with OpenAI, to expedite the drug approval process. This initiative, led by the FDA's first AI officer, aims to modernize regulatory reviews, although concerns about AI reliability and proper data training persist.

The FDA has launched Elsa, a generative AI tool aimed at enhancing operational efficiency across the agency. Designed to assist employees with tasks such as reading, writing, and summarizing, Elsa will streamline processes like clinical protocol reviews and safety profile assessments while ensuring data security. This initiative marks the beginning of the FDA's broader integration of AI technologies.